These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27619835)

  • 1. Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.
    Carignan A; Poulin S; Martin P; Labbé AC; Valiquette L; Al-Bachari H; Montpetit LP; Pépin J
    Am J Gastroenterol; 2016 Dec; 111(12):1834-1840. PubMed ID: 27619835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridiodes difficile infection relapses.
    Caroff DA; Menchaca JT; Zhang Z; Rhee C; Calderwood MS; Kubiak DW; Yokoe DS; Klompas M
    Infect Control Hosp Epidemiol; 2019 Jun; 40(6):662-667. PubMed ID: 31030679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.
    Morrisette T; Van Matre AG; Miller MA; Mueller SW; Bajrovic V; Abidi MZ; Benamu E; Kaiser JN; Barber GR; Chase S; Tobin J; Fish DN; Gutman JA
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):2091-2097. PubMed ID: 31255741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of
    Knight EM; Schiller DS; Fulman MK; Rastogi R
    J Pharm Pract; 2020 Oct; 33(5):633-639. PubMed ID: 30744479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary prophylaxis for Clostridioides difficile infection for patients on non-C. difficile antibiotics: a retrospective cohort study.
    Najjar-Debbiny R; Barnett-Griness O; Arbel A; Cohen S; Weber G; Amar M; Yassin R; Greenfeld I; Shehadeh S; Saliba W
    Microbes Infect; 2024; 26(5-6):105349. PubMed ID: 38719086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Vancomycin as Secondary Prophylaxis for
    Bao H; Lighter J; Dubrovskaya Y; Merchan C; Siegfried J; Papadopoulos J; Jen SP
    Pediatrics; 2021 Aug; 148(2):. PubMed ID: 34330867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection.
    Zhang K; Beckett P; Abouanaser S; Stankus V; Lee C; Smieja M
    BMC Infect Dis; 2019 Jan; 19(1):51. PubMed ID: 30642269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin Prophylaxis for Prevention of Clostridium difficile Infection Recurrence in Renal Transplant Patients.
    Splinter LE; Kerstenetzky L; Jorgenson MR; Descourouez JL; Leverson GE; Saddler CM; Smith JA; Safdar N; Redfield RR
    Ann Pharmacother; 2018 Feb; 52(2):113-119. PubMed ID: 28844154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection.
    McDonald EG; Milligan J; Frenette C; Lee TC
    JAMA Intern Med; 2015 May; 175(5):784-91. PubMed ID: 25730198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
    Prabhu VS; Dubberke ER; Dorr MB; Elbasha E; Cossrow N; Jiang Y; Marcella S
    Clin Infect Dis; 2018 Jan; 66(3):355-362. PubMed ID: 29106516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral Vancomycin Monotherapy Versus Combination Therapy in Solid Organ Transplant Recipients With Uncomplicated Clostridium difficile Infection: A Retrospective Cohort Study.
    Korayem GB; Eljaaly K; Matthias KR; Zangeneh TT
    Transplant Proc; 2018; 50(1):137-141. PubMed ID: 29407296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel.
    Na'amnih W; Adler A; Miller-Roll T; Cohen D; Carmeli Y
    Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1281-1288. PubMed ID: 29627951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis?
    Allegretti JR; Kao D; Phelps E; Roach B; Smith J; Ganapini VC; Kassam Z; Xu H; Fischer M
    Dig Dis Sci; 2019 Jun; 64(6):1668-1671. PubMed ID: 30632052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy.
    Bouza E; Alcalá L; Marín M; Valerio M; Reigadas E; Muñoz P; González-Del Vecchio M; de Egea V
    Eur J Clin Microbiol Infect Dis; 2017 Oct; 36(10):1777-1786. PubMed ID: 28501926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
    Kimura T; Snijder R; Sugitani T
    J Infect Chemother; 2019 Aug; 25(8):615-620. PubMed ID: 30987950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of antibiotics and case exposure on hospital-acquired Clostridium difficile infection independent of illness severity.
    Forster AJ; Daneman N; van Walraven C
    J Hosp Infect; 2017 Apr; 95(4):400-409. PubMed ID: 27825674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of fidaxomicin versus oral vancomycin in the treatment of recurrent clostridioides difficile.
    Rinaldi A; Reed EE; Stevenson KB; Coe K; Smith JM
    J Clin Pharm Ther; 2021 Aug; 46(4):993-998. PubMed ID: 33609052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
    Tieu JD; Williams RJ; Skrepnek GH; Gentry CA
    J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral vancomycin prophylaxis against recurrent
    Zacharioudakis IM; Zervou FN; Dubrovskaya Y; Phillips MS
    Infect Control Hosp Epidemiol; 2020 Aug; 41(8):908-913. PubMed ID: 32539877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton Pump Inhibitors Do Not Increase Risk for Clostridium difficile Infection in the Intensive Care Unit.
    Faleck DM; Salmasian H; Furuya EY; Larson EL; Abrams JA; Freedberg DE
    Am J Gastroenterol; 2016 Nov; 111(11):1641-1648. PubMed ID: 27575714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.